Innovative platform to screen CAR-T/TCR cancer immunotherapy drugs for off-target binding

筛选 CAR-T/TCR 癌症免疫治疗药物脱靶结合的创新平台

• 批准号: 104699
• 金额: $ 28.51万
• 依托单位: ORBIT DISCOVERY LTD
• 依托单位国家: 英国
• 项目类别: Feasibility Studies
• 财政年份: 2019
• 资助国家: 英国
• 起止时间: 2019 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=104699
• 关键词: Innovative; platform; screen; CAR; TCR

Orbit Discovery Ltd was established in November 2015 as a spin-out from Oxford University. The founding IP relates to a peptide display platform and its use for the identification of novel peptides and for the identification of T-cell epitopes in high throughput screens. We provide services identifying and characterising advanced therapeutics for a range of chronic diseases.**Target Markets**Companies making modified TCRs as drug products for Cancer Immunotherapy have a current pressing need to identify off-target binding of their products to ensure safety; there have been several reported patient deaths in clinical trials due to cardiac or gastric inflammation as a direct result of treatment with modified TCRs.**Project Description**This project aims to investigate and validate a broad screening solution that would enable these companies to more comprehensively and reliably screen their products earlier in development. This would reduce the risk of medical side-effects or fatalities during clinical trials and would speed up the development and deployment of more effective cancer treatments.

Orbit Discovery Ltd成立于2015年11月，是牛津大学的一个分支。发明IP涉及肽展示平台及其在高通量筛选中用于鉴定新型肽和用于鉴定T细胞表位的用途。我们为一系列慢性疾病提供先进疗法的鉴定和表征服务。**目标市场 ** 生产经修饰的TCR作为癌症免疫治疗药物产品的公司目前迫切需要确定其产品的脱靶结合以确保安全性;在临床试验中，有几例患者因心脏或胃部炎症而死亡，这是使用经修饰的TCR治疗的直接结果。** 本项目旨在研究和验证一种广泛的筛选解决方案，使这些公司能够在开发早期更全面可靠地筛选其产品。这将降低临床试验期间的医疗副作用或死亡风险，并将加快更有效的癌症治疗方法的开发和部署。